Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.

ABSTRACT:

Background

Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the methylation profile have been implicated as one of the mechanisms through which therapy resistance develops. Therefore, we aimed to identify methylation loci associated with endocrine therapy resistance.

Methods

We used genome-wide DNA methylation profiles of primary ER+/HER2- tumours from The Cancer Genome Atlas in combination with curated data on survival and treatment to predict development of endocrine resistance. Association of individual DNA methylation markers with survival was

SUBMITTER: Soleimani Dodaran M 

PROVIDER: S-EPMC7368985 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature